New hope for kidney transplant patients: safer CMV prevention on the horizon?
NCT ID NCT06001320
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 27 times
Summary
This study tests whether a newer drug, letermovir, works better and causes fewer side effects than the standard drug valganciclovir for preventing CMV infection in African American kidney transplant recipients. About 30 high-risk patients will take letermovir for 6 months after transplant, and their results will be compared to a similar group who took valganciclovir. The goal is to see if letermovir can reduce the risk of CMV while causing less harm to white blood cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
VCU Medical Center
Richmond, Virginia, 23219, United States
Conditions
Explore the condition pages connected to this study.